180 related articles for article (PubMed ID: 16006240)
1. Mapping of B-cell epitopes in E. coli asparaginase II, an enzyme used in leukemia treatment.
Werner A; Röhm KH; Müller HJ
Biol Chem; 2005 Jun; 386(6):535-40. PubMed ID: 16006240
[TBL] [Abstract][Full Text] [Related]
2. Comparative immunogenicity and structural analysis of epitopes of different bacterial L-asparaginases.
Pokrovsky VS; Kazanov MD; Dyakov IN; Pokrovskaya MV; Aleksandrova SS
BMC Cancer; 2016 Feb; 16():89. PubMed ID: 26867931
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoanalytical assays of Erwinia asparaginase (erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of erwinase population PK-PD models.
Avramis VI; Martin-Aragon S; Avramis EV; Asselin BL
Anticancer Res; 2007; 27(4C):2561-72. PubMed ID: 17695416
[TBL] [Abstract][Full Text] [Related]
4. Optimizing asparaginase therapy for acute lymphoblastic leukemia.
Rizzari C; Conter V; Starý J; Colombini A; Moericke A; Schrappe M
Curr Opin Oncol; 2013 Mar; 25 Suppl 1():S1-9. PubMed ID: 23380829
[TBL] [Abstract][Full Text] [Related]
5. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
Earl M
Clin Adv Hematol Oncol; 2009 Sep; 7(9):600-6. PubMed ID: 20020672
[TBL] [Abstract][Full Text] [Related]
6. Development of anti-asparaginase antibodies in childhood acute lymphoblastic leukemia.
Zalewska-Szewczyk B; Andrzejewski W; Bodalski J
Pediatr Blood Cancer; 2004 Oct; 43(5):600-2. PubMed ID: 15382279
[TBL] [Abstract][Full Text] [Related]
7. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
8. A structural in silico analysis of the immunogenicity of l-asparaginase from Escherichia coli and Erwinia carotovora.
Belén LH; Lissabet JB; de Oliveira Rangel-Yagui C; Effer B; Monteiro G; Pessoa A; Farías Avendaño JG
Biologicals; 2019 May; 59():47-55. PubMed ID: 30871932
[TBL] [Abstract][Full Text] [Related]
9. A desensitization protocol in children with L-asparaginase hypersensitivity.
Akbayram S; Doğan M; Akgün C; Caksen H; Oner AF
J Pediatr Hematol Oncol; 2010 Jul; 32(5):e187-91. PubMed ID: 20505537
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and drug monitoring of L-asparaginase treatment.
Boos J
Int J Clin Pharmacol Ther; 1997 Mar; 35(3):96-8. PubMed ID: 9088996
[TBL] [Abstract][Full Text] [Related]
11. Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.
Figueiredo L; Cole PD; Drachtman RA
Expert Rev Hematol; 2016 Mar; 9(3):227-34. PubMed ID: 26765930
[TBL] [Abstract][Full Text] [Related]
12. Proteins from Erwinia asparaginase Erwinase ® and E. coli asparaginase 2 MEDAC ® for treatment of human leukemia, show a multitude of modifications for which the consequences are completely unclear.
Bae N; Pollak A; Lubec G
Electrophoresis; 2011 Jul; 32(14):1824-8. PubMed ID: 21769889
[TBL] [Abstract][Full Text] [Related]
13. Alternative algorithm for L-asparaginase allergy in children with acute lymphoblastic leukemia.
Soyer OU; Aytac S; Tuncer A; Cetin M; Yetgin S; Sekerel BE
J Allergy Clin Immunol; 2009 Apr; 123(4):895-9. PubMed ID: 19081614
[TBL] [Abstract][Full Text] [Related]
14. Hypersensitivity reactions to asparaginase therapy in acute lymphoblastic leukemia: immunology and clinical consequences.
Burke MJ; Zalewska-Szewczyk B
Future Oncol; 2022 Mar; 18(10):1285-1299. PubMed ID: 35107320
[TBL] [Abstract][Full Text] [Related]
15. Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low dose of E. coli L-asparaginase: a GIMEMA study.
Leone G; Gugliotta L; Mazzucconi MG; De Stefano V; Belmonte MM; Dragoni F; Specchia G; Centra A; Gamba G; Camera A
Thromb Haemost; 1993 Jan; 69(1):12-5. PubMed ID: 8446931
[TBL] [Abstract][Full Text] [Related]
16. Rhizobium etli asparaginase II: an alternative for acute lymphoblastic leukemia (ALL) treatment.
Huerta-Saquero A; Evangelista-Martínez Z; Moreno-Enriquez A; Perez-Rueda E
Bioengineered; 2013; 4(1):30-6. PubMed ID: 22895060
[TBL] [Abstract][Full Text] [Related]
17. Tracking Silent Hypersensitivity Reactions to Asparaginase during Leukemia Therapy Using Single-Chip Indirect Plasmonic and Fluorescence Immunosensing.
Charbonneau DM; Breault-Turcot J; Sinnett D; Krajinovic M; Leclerc JM; Masson JF; Pelletier JN
ACS Sens; 2017 Dec; 2(12):1761-1766. PubMed ID: 29168384
[TBL] [Abstract][Full Text] [Related]
18. Monitoring of anti-L-asparaginase antibody and L-asparaginase activity levels in a pediatric patient with acute lymphoblastic leukemia and hypersensitivity to native Escherichia coli L-asparaginase during desensitization courses.
Kawahara Y; Morimoto A; Hayase T; Kashii Y; Fukuda T; Momoi MY
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e91-3. PubMed ID: 23689289
[TBL] [Abstract][Full Text] [Related]
19. Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display.
Mullaney BP; Pallavicini MG; Marks JD
Infect Immun; 2001 Oct; 69(10):6511-4. PubMed ID: 11553596
[TBL] [Abstract][Full Text] [Related]
20. [Allergic reactions in treatment with L-asparaginase. Significance of specific IgE antibodies].
Körholz D; Wahn U; Jürgens H; Wahn V
Monatsschr Kinderheilkd; 1990 Jan; 138(1):23-5. PubMed ID: 2314401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]